Relationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinoma

Mostrar otras versiones (1)

BACKGROUND: Pazopanib, an oral angiogenesis inhibitor targeting vascular endothelial growth factor receptor (VEGFR)/platelet-derived growth factor receptor (PDGFR)/c-Kit, is approved in locally advanced/metastatic renal cell carcinoma (RCC). METHODS: Data from trials in advanced solid tumours and ad...

Descripción completa

Detalles Bibliográficos
Autores principales: Suttle, A B, Ball, H A, Molimard, M, Hutson, T E, Carpenter, C, Rajagopalan, D, Lin, Y, Swann, S, Amado, R, Pandite, L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2014
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4229638/
https://www.ncbi.nlm.nih.gov/pubmed/25349968
http://dx.doi.org/10.1038/bjc.2014.503

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4229638/
https://www.ncbi.nlm.nih.gov/pubmed/25349968
http://dx.doi.org/10.1038/bjc.2014.503

Ejemplares similares